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Objective: Nerve growth factor (NGF) has a pivotal role in peripheral hyperalgesia and inflammation;
anti-NGF antibodies attenuate pain responses in inflammatory pain models, and in people with osteo-
arthritis (OA) or low back pain. The aim of this study was to characterise the peripheral mechanisms
contributing to the analgesic effects of anti-NGF antibody treatment in an established model of joint pain,
which mimics key clinical features of OA.
Design: Effects of preventative vs therapeutic treatment with an anti-NGF antibody (monoclonal anti-
body 911: muMab 911 (10 mg/kg, s.c.)) on pain behaviour (weight bearing asymmetry and hindpaw
withdrawal thresholds (PWT)), cartilage damage, synovitis and numbers of subchondral osteoclasts were
investigated in the monosodium iodoacetate (MIA) model. Potential direct effects of NGF on receptor
activator of nuclear factor kappa-B ligand (RANKL) mediated osteoclastogenesis were investigated in
cultured human osteoclasts.
Results: Intra-articular MIA injection resulted in significant pain behaviour, cartilage damage, synovitis
and increased numbers of subchondral osteoclasts. Both preventative and therapeutic treatment with
muMab 911 significantly prevented, or reversed, MIA-induced pain behaviour, but did not alter cartilage
or synovial pathology quantified at the end of the treatment period. NGF did not facilitate RANKL driven
osteoclast differentiation in vitro, but preventative or therapeutic muMab 911 reduced numbers of TRAP
positive osteoclasts in the subchondral bone.
Conclusions: We demonstrate that anti-NGF antibody treatment attenuates OA pain behaviour despite
permitting cartilage damage and synovitis. Indirect effects on subchondral bone remodelling may
contribute to the analgesic effects of NGF blockade.
© 2016 The Authors. Published by Elsevier Ltd on behalf of Osteoarthritis Research Society International.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).Introduction
Osteoarthritis (OA) is themost common form of arthritis and the
fastest growing chronic pain disease worldwide1, prevalence of OA
increases with age2. All compartments of OA joints undergo struc-
tural changes, which impacts upon function, causing disability andto: V. Chapman, Arthritis
ottingham, UK.
uk (V. Chapman).
r Ltd on behalf of Osteoarthritis Rereducing quality of life2. Joint structural changes associatedwith OA
pain include synovitis3 and bone marrow lesions4. OA pain is char-
acterised by both pain on loading and spread of pain to sites remote
from the diseased joint, and clinical evidence supports a contribu-
tion of both peripheral and central sensitization mechanisms to OA
pain5. The challenge of identifying analgesic strategies that more
effectively target OA pain requires a comprehensive understanding
of the underlying pain mechanisms. Rodent models which mimic
aspects of the clinical pathology and exhibit pain on loading (weight
bearing) and lowering of paw withdrawal thresholds (PWT) at
remote sites6 play a pivotal role in elucidating mechanisms of OA
pain, which cannot be readily interrogated in clinical studies.search Society International. This is an open access article under the CC BY license
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chronic pain. NGF binds to high affinity tropomyosin-receptor-
kinase A (TrkA) and low affinity p75 neurotrophin receptors on
sensory nerve terminals and immune cells, and has an established
role in peripheral hyperalgesia associated with inflammation7. In-
jection of NGF into the knee induces pain behaviour and synovitis
in naïve rats, and exacerbates established pain behaviour in a
model of OA pain8. The neuronal basis for these behavioural effects
of exogenous NGF is likely to include an expansion of knee joint
peripheral receptive fields of spinal neurones9. NGF levels are
increased in arthritic joints, within the inflamed synovium and
osteochondral junction10,11. NGF is known to sensitise peripheral
nerves and might stimulate blood vessel and nerve growth into
structures such as the articular cartilage that are not normally
innervated12. However, whether endogenous NGF contributes to
the synovitis and joint pathology associated with OA pain, as well
as the direct sensitization of sensory nerves, is unknown. NGF
blockade can be achieved using antibodies or TrkA-IgG fusion
protein that bind NGFand prevent its interactionwith TrkA and p75
receptors. Humanised monoclonal antibodies against NGF have
robust analgesic effects in OA sufferers13,14. However, unexpected
findings of rapidly progressive OA (RPOA) in some participants,
unrelated to the extent of pain relief15, has highlighted the need for
further mechanistic studies. To address this gap in knowledge the
aim of the present study was to investigate the peripheral mech-
anisms that underpin the analgesic effects of sequestering NGF. To
this end we have compared the effects of preventative vs thera-
peutic treatment with the anti-NGF sequestering antibody muMab
911 on two indices of pain, weight bearing asymmetry (pain on
loading) and lowered hindpaw withdrawal thresholds (distal pain)
with parallel measures of joint pathology (chondropathy, synovitis
and numbers of subchondral osteoclasts) in an establishedmodel of
OA pain. To determine whether a potential direct effect of NGF on
osteoclast differentiation underpins the inhibitory effects of
muMab 911 in vivo, effects of NGF treatment on RANKL and non-
RANKL mediated differentiation of human monocytes into osteo-
clasts was studied.
Methods
Animal and model induction
Studies were conducted in accordance with UK Home Office
Animals (Scientific Procedures) Act (1986) and guidelines of the
International Association for the Study of Pain. Study approval was
granted by the University of Nottingham Ethics committee. The
experimenter was blind to all interventions. 130 male Sprague
Dawley rats (140e260 g (5e7 weeks old) Charles River UK) were
group housed, had free access to food and water and were on a 12 h
light/dark cycle. Group sizes were n ¼ 10, data points which were
statistical outliers (median ± 2 standard deviations) were excluded
and final numbers are reported below. Rats were anaesthetised
(isoflurane) and received intra-articular injection of monosodium
iodoacetate (MIA; 1 mg/50 ml; Sigma UK) in saline, or saline (50 ml)
as a control, through the infra-patellar ligament of the left knee on
Day 06. Post-injection rats were group housed (5 per cage) and their
posture and behaviour was closely monitored for 48 h. Pain
behaviour was assessed in the laboratory in the morning prior to
intra-articular injection on Day 0 as weight bearing asymmetry
(using an incapacitance tester (Linton Instrumentation, UK), a
behavioural correlate of hyperalgesia, and hind paw mechanical
withdrawal thresholds (Semmes-Weinstein monofilaments of
bending forces 1e26 g), an index of central sensitization6. Four
independent studies were performed in MIA and saline control
rats: effect of preventative treatment vs vehicle on pain behaviourand joint pathology up to day 28 (data reported on 38 rats); effect of
therapeutic treatment vs vehicle on pain behaviour and joint pa-
thology up to day 28 (data reported on 38 rats); effect of a pre-
ventative treatment of IgG1 vs vehicle on pain behaviour up to day
28 (data reported on 30 rats) evaluation of joint pathology at day 14
in MIA and saline control rats (data reported for 19 rats).
Drug treatments and administration protocols
Rats were habituated to the pain behavioural tests and subcu-
taneous injections. Effects of the anti-NGF sequestering antibody
(monoclonal antibody 911, muMab 911; provided by Dr David
Shelton, Rinat/Pfizer, San Francisco, CA)16 were determined in the
MIA model. MuMab 911 blocks binding of NGF to TrkA and p75NTR
receptors, inhibits TrkA auto-phosphorylation16, has a plasma half-
life of 5e6 days in the rodent and low blood brain barrier perme-
ability17. The preventative study used weekly dosing of muMab 911
(s.c. 10 mg/kg) or PBS from Day 0 (Supplementary fig. 1(A),
n ¼ 8e10 rats per group). Two types of control were used, mag-
nesium and calcium free phosphate buffered saline (PBS) as the
vehicle control and an IgG control specific for muMab 911 (s.c.
10 mg/kg), which was administered to a separate cohort of rats
using the preventative treatment protocol identical to that outlined
in Supplementary fig. 1(A) (n ¼ 10 rats per group). The therapeutic
study used dosing of muMab 911 (s.c. 10 mg/kg) or PBS on Day 14
and 21 post-MIA injection (Supplementary fig. 1(B)). MIA groups
were matched according to weight bearing asymmetry prior to
treatment by an independent experimenter. Cohorts consisted of
both sham and MIA rats treated with either vehicle or muMab 911,
experimenters blinded to all treatments. This dose of muMab 911
attenuated hyperalgesia in auto-immune arthritis17 and bone
cancer pain18. Pain behaviour was assessed twice weekly after
model induction, studies were terminated on Day 28
(Supplementary fig. 1). On the basis of previous unpublished
studies, muMab 911was expected to cause aminor skin irritation in
some rats. These were quantified as mild if the skin lesion was
<0.4 cm in diameter without bleeding, moderate if therewas one or
more area(s) of skin lesion with a diameter >0.4 cm, with or
without bleeding. Rats exhibiting either mild or moderate skin
irritation were treated topically with fuciderm gel (0.5% w/w
Fusidic acid, 0.1% w/w Betamethasone).
Histology
Rats were overdosed with pentobarbital (i.p.) at sacrifice.
Tibiofemoral joints were removed and post-fixed in neutral buff-
ered formalin (4% formaldehyde), decalcified in 10% ethyl-
enediaminotetraacetic acid (EDTA) for 6e8 weeks6 and embedded
in paraffin wax. Histomorphometry was carried out by an observer
blinded to treatment. Full details of the tissue section preparation
and processing is provided in the supplementary section. Coronal
tissue sections were cut at 5 mm following the Osteoarthritis
Research Society International (OARSI) guideline for histological
assessment for OA in the rat19. Haematoxylin and eosin stained
sections were scored for articular cartilage surface integrity and
synovial inflammation6,20. Quantification of numbers of tartrate-
resistant acid phosphatase (TRAP) positive osteoclasts was
perform as previously described21.
In vitro model of human osteoclast differentiation
This study was approved by the Nottingham University Medical
School Research Ethics Committee. Full details of the methods of
in vitromodel of human osteoclast differentiation is provided in the
Supplementary section. In brief, peripheral blood from healthy
L. Xu et al. / Osteoarthritis and Cartilage 24 (2016) 1587e1595 1589human donors was collected and blood monocytes were isolated
from buffy coats by gradient centrifugation, monocytes were
seeded onto glass coverslips within a 24-well culture plates, and
cultured in growth media supplemented with human macrophage
colony stimulating factor (MCSF; R&D Systems) and with
30 ng ml1 of human RANKL (Santa Cruz), unless otherwise stated.
Cells were incubated at 37C, 7% CO2 for 2 h, and the medium
replaced. Growth media containing NGF (0e200ngml1 was then
added to the cells. After 14 days, cells were washed with Hanks
buffered saline solution, fixed with 10% neutral buffered formalin,
washed and stored at 4C in PBS containing 0.01% w/v sodium
azide.
Differentiated osteoclasts were identified by TRAP staining us-
ing the commercial kit described above. For quantification of TRAP
positive cells four random fields of viewwere counted per coverslip
using four coverslips per condition. Cells that stained positive for
TRAP and had three or more nuclei were counted.Fig. 1. Preventative muMab 911 attenuates OA pain behaviour but not cartilage damage o
of 10 mg/kg muMab 911 or PBS on days 0, 7, 14, and 21 post intra-articular injection of MIA o
bearing asymmetry (A, B) and attenuated hindpaw withdrawal thresholds (C, D). Statistical
tests, *P < 0.05, **P < 0.01, ***P < 0.001: MIA vs saline; #P < 0.05, ##P < 0.01, ###P < 0.00
group, and is not shown for clarity (n ¼ 10 rats per group). Preventative treatment with muM
(E) or synovial inflammation (n ¼ 8e9 per group) (F). *P < 0.05, **P < 0.01, ***P < 0.001 v
neWhitney U-test. Comparisons of histology between groups used a Kruskal Wallis test
interquartile range. M911: muMab 911.Statistical analysis
Data were tested for normality prior to statistical analysis. Data
points were classified as outliers if they exceeded the mean ± 2
standard deviations, final group sizes are reported in figure legends.
Comparisons of pain behaviour between groups of rats at different
time points were carried out using two-way ANOVA with Bonfer-
roni's post-hoc tests. To address potential multiplicity, area under
the curve analysis of timecourse data was also performed with a
ManneWhitney U-test. Comparisons of osteoclast numbers be-
tween groups used a one-way ANOVA with Bonferroni's post-hoc
test. Associations between osteoclast numbers and pain behaviour
inMIA-injected rats treatedwithmuMab 911 or vehiclewere tested
by pooling data from preventative and therapeutic treatment pro-
tocols, using linear (weight bearing asymmetry) or logistic (PWT)
regression, with adjustment for possible between experiment
variation by including experiment number as a covariate. Due tor synovitis in the MIA model of OA pain. Rats received weekly subcutaneous injection
r saline. Preventative muMab 911 robustly prevented MIA-induced changes in weight-
comparison of groups at each timepoint: two-Way ANOVA with Bonferroni's post-hoc
1 muMab 911 vs PBS. Note saline muMab 911 group did not differ from the saline PBS
ab 911 did not significantly alter MIA-induced cartilage damage (n ¼ 9e10 per group)
s saline-PBS. Comparisons between Areas Under Curve were performed using a Man-
with Dunn's post hoc. A, C: data are mean ± SEM; B, D, E, F: data are median and
L. Xu et al. / Osteoarthritis and Cartilage 24 (2016) 1587e15951590the ordinal nature of joint structure and inflammation scores, data
were non-normally distributed and comparisons between groups
used a Kruskal Wallis test with post hoc Dunn's test. P < 0.05 was
statistically significant. Analysis of in vitro TRAP assays was per-
formed with a either a one way ANOVA with Dunnett's test (more
than two group compared) or with a unpaired two-tailed Man-
neWhitney t-test (two groups compared).Results
Effects of preventative muMab 911 on MIA-induced pain behaviour
and changes in joint structure
Intra-articular injection of MIAwas associated with a significant
increase in weight bearing asymmetry and a significant decrease in
ipsilateral hindpaw withdrawal thresholds, compared to intra-
articular injection of saline [Fig. 1(A), (C)]. Preventative treatment
with muMab 911 (10 mg/kg weekly) from Day 0 robustly prevented
the development of weight-bearing asymmetry (Fig. 1(A);
F(3,360 ¼ 40.88, MS ¼ 2816, P < 0.0001). Effects of muMab 911 on
MIA-induced lowering of hindpawwithdrawal thresholds were less
immediate, and only significant on day 28 [Fig. 1(C)]. AUC analysis
only revealed a significant effect of muMab 911 on weight-bearing
asymmetry [Fig. 1(B), (D)]. MuMab 911 did not alter weight-bearing
or hindpaw withdrawal thresholds in saline injected rats (data not
shown). Preventative administration of control IgG1 did not alter
MIA-induced changes in weight bearing or PWT, compared to PBS-
treated MIA-injected rats (Supplementary fig. 2).
The MIA model was associated with changes in the articular
cartilage of the knee joint, measured as joint damage scoreFig. 2. Preventative muMab 911 and cartilage damage or synovitis in the MIA model of
treated saline-injected control showing an intact joint with smooth cartilage, normal joint m
structural pathology: cartilage damage (green arrows); chondrocyte loss (green arrows); su
pathology to the MIA-PBS treated rat (B). D: 1e2 cell deep synovial lining layer (blue arrow) i
injected PBS-treated rat. F: Synovium from a M911-treated MIA-injected rat exhibited simila
eosin stained sections of knee tissue from a rat with the median pathology score from e
sb ¼ subchondral bone and s ¼ synovium.[Fig. 1(E)] and synovial inflammation [Fig. 1(F)], compared to saline
injected rats [Fig. 2(A)e(F)]. Preventative treatment with muMab
911 did not significantly alter these MIA-induced changes in the
knee joint [Fig. 1(E), (F), Fig. 2(A)e(F)].
The MIA model was also associated with an increase in the
number of TRAP positive osteoclasts at the tibial plateau, compared
to saline injected rats [Fig. 3(A), (C)]. There was a significantly
higher number of TRAP positive osteoclasts at the tibial plateau of
MIA rats receiving preventative vehicle, compared to MIA rats
receiving preventative muMab 911 (Fig. 3(A); F (3, 34) ¼ 22.83,
MS ¼ 3838, P < 0.0001). There was no significant difference in the
number of TRAP positive osteoclasts at the tibial plateau fromMIA-
injected rats treated with preventative muMab 911 and saline
injected rats [Fig. 3(A), (C)].Effects of therapeutic muMab 911 on MIA-induced pain behaviour
and changes in joint structure
The MIA model was associated with a significant increase in
weight bearing asymmetry and lowering of hindpaw withdrawal
thresholds, there were no differences between the magnitudes of
these measures in the two groups of MIA rats prior to the start of
the therapeutic treatment [Fig. 4(A), (C)]. Therapeutic muMab 911
(10 mg/kg, s.c, day 14 and 21) significantly reversed pain behaviour
in MIA-injected rats (Fig. 4(A); F(3,340) ¼ 68.67, MS ¼ 5293,
P < 0.0001; Fig. 4(C); F(3,330)¼ 22.54, MS¼ 1812, P < 0.0001). AUC
analysis revealed a significant reversal in weight bearing asym-
metry and lowered hindpaw withdrawal thresholds over the
duration of the study [Fig. 4(B), (D)].OA pain. Histological sections of osteochondral (AeC) or synovial (DeF) tissue. A; PBS-
argin and chondrocyte morphology. B; 1 mg MIA-injected PBS-treated rat showing OA
bchondral bone changes (asterisk). C: M911-treated MIA-injected rat exhibited similar
n PBS-treated saline-injected control. E; Synovial hyperplasia (red arrows) in 1 mg MIA-
r pathology to the MIA-PBS treated rat (E). Photomicrographs show haematoxylin and
ach group. Scale bars ¼ 200 mm. F ¼ femur, m ¼ meniscus, c ¼ cartilage, t ¼ tibia,
Fig. 3. Preventative and therapeutic muMab 911 attenuates the number of TRAP positive osteoclasts in the tibial plateau in MIA rats. (A) The number of TRAP positive
osteoclasts in the tibial plateau was significantly increased in MIA rats receiving vehicle treatment. Preventative treatment with muMab 911 significantly reduced the number of
TRAP positive osteoclasts in MIA rats. Data are mean ± SEM, n ¼ 9e10 per group. (B) Therapeutic muMab 911 significantly attenuated the MIA-induced increase in the number of
TRAP positive osteoclasts in the tibial plateau. Data are mean ± SEM n ¼ 8e10 per group. Statistical comparison was carried out using one-Way ANOVA with Bonferroni's post-hoc
tests, *P < 0.05, **P < 0.01. Representative images of osteoclasts at the osteochondral junction of the tibial plateau in a saline-PBS rat (left), MIA-PBS rat (middle) and MIA-muMab
911 rat (right) in the preventative study (C) and therapeutic study (D). Images were taken with a Zeiss Axioplan microscope at 10 magnification. Arrows indicate multinucleated
TRAP positive osteoclasts. M911: muMab 911.
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lage and synovial inflammation grades, compared to saline controls
[Fig. 4(E), (F)]. Therapeutic treatment with muMab 911 did not
significantly alter the MIA-induced changes in joint structure, nor
the extent of synovial inflammation, compared toMIA-injected rats
receiving vehicle [Fig. 4(E), (F)].
MIA-injected rats had a significant increase in the number of
TRAP positive osteoclasts at the tibial plateau at 28 days, compared
to saline controls [Fig. 3(B)]; numbers were comparable between
the groups used for the preventative and therapeutic experiments. .
At day 14 post MIA injection there is a significant (ManneWhitney
U ¼ 8.500, P ¼ 0.016) increase in the number of TRAP positive os-
teoclasts in the subchondral bone of MIA treated rats (66 ± 9, n ¼ 9
rats), compared to saline treated rats (33 ± 3, n ¼ 10 rats). Thera-
peutic muMab 911 treatment from day 14 significantly attenuated
the numbers of TRAP positive osteoclasts at 28 days in the MIA rats,
compared to MIA rats treated with vehicle (Fig. 3(B), (D): F (3,
34) ¼ 7.047, MS ¼ 2138, P ¼ 0.0008).Numbers of TRAP positive osteoclasts in the rats that had
received intra-articular injection of MIA and either preventative or
therapeutic treatments with muMab 911 or vehicle were positively
associated with weight-bearing asymmetry (standardised
beta ¼ 0.35, P ¼ 0.04), but the association with PWT did not reach
statistical significance (aOR¼ 1.04, 95% CI¼ 0.997 to1.075, P¼ 0.07).
Effects of NGF on RANKL mediated osteoclast differentiation
To determine whether the inhibitory effects of muMab 911 on
numbers of subchondral osteoclasts in vivo is likely to arise from a
direct effect of NGF on osteoclast differentiation we investigated
the effect of NGF treatment on RANKL and non-RANKL mediated
differentiation of human monocytes into osteoclasts. Incubation of
monocytes with RANKL (30ngml1) resulted in a robust increase in
the number of TRAP positive multinucleated osteoclasts [Fig. 5(A)].
Lower concentrations of NGF (50 and ngml1) significantly
decreased the number of TRAP positive multinucleated osteoclasts,
Fig. 4. Therapeutic muMab 911 attenuates established OA pain behaviour but not cartilage damage and synovitis in the MIA model of OA pain. Rats received subcutaneous
injection of 10 mg/kg muMab 911 or PBS on days 14 and 21 post intra-articular injection of MIA. muMab 911 treatment alleviated MIA-induced changes in weight-bearing
asymmetry (A, B) and attenuated hindpaw withdrawal thresholds (C, D). Statistical comparison of muMab 911 and PBS treatment on pain behaviour, A, C are mean ± SEM
(n ¼ 8e10 rats per group): two-Way ANOVA with Bonferroni's post-hoc tests, #P < 0.05, ###P < 0.001. Note behavioural data from rats which received intra-articular injection of
saline were comparable to the preventative study, and are not shown for clarity. B, D are median and interquartile range, comparison of these data was performed with a Man-
neWhitney U-test, #P < 0.05, ##P < 0.01. Therapeutic treatment with muMab 911 did not significantly alter MIA-induced cartilage damage (E) or synovial inflammation (F)
(n ¼ 8e10 rats per group). E, F are median and interquartile range, comparisons between groups used a Kruskal Wallis test with Dunn's post hoc comparison. *P < 0.05, **P < 0.01,
***P < 0.001. M911: muMab 911.
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[Fig. 5(A)]. In the absence of RANKL, the numbers of TRAP positive
multinucleated osteoclasts was markedly lower. NGF resulted in a
small but significant concentration-independent increase in the
number of TRAP positive multinucleated osteoclasts [Fig. 5(B)].Other effects of muMab 911
The appearance of expected adverse effects of muMab 911 was
monitored. From Day 12 onwards of the preventative muMab 911,
some rats exhibited skin irritation (Supplementary Table 1), which
were treated with fuciderm gel. There were no differences in the
MIA-induced pain behaviour between rats exhibiting, or not,
adverse effects. One rat in the therapeutic study exhibited an
adverse effect on Day 28 (Supplementary Table 1). Systemic
muMab 911 treatment did not alter body weight gain compared
with vehicle treatment (Supplementary fig. 3).Discussion
Preventative or therapeutic treatment with muMab 911
significantly prevented, or reversed, MIA-induced pain behav-
iour. The analgesic effects of this treatment were not associated
with significant changes in chondropathy or synovial inflam-
mation, but were associated with a significant reduction in the
number of TRAP positive multinucleated osteoclasts at the tibial
plateau in the model of OA. As in human OA22, the MIA model of
OA in the rodent exhibits bone remodeling23,24 and excessive
osteoclast activity, which is significantly correlated with the
magnitude of pain behavior as demonstrated previously6 and
herein.
The analgesic effects of muMab 911 in the MIAmodel of OA pain
are consistent with the report that the soluble NGF receptor
TrkAD5, which like muMab 911 binds to NGF, blocks early and late
changes in weight distribution in the DMM mouse model of OA25
and our recent report that blocking the TrkA receptor with a
Fig. 5. Effects of NGF upon osteoclast differentiation in vitro. Human peripheral mononuclear cells were isolated and cultured in the presence of MCSF with (A) or without (B)
RANKL, and increasing concentrations of NGF, for 14 days. TRAP þve cells were counted using four random fields of vision on four separate slides for each condition. RANKL alone
significantly increased TRAP þve cells as compared to MCSF alone (A). For RANKL treated cells, addition of NGF significantly decreased osteoclast numbers at 50 and 100 ng/ml. In
the absence of RANKL (B), addition of NGF caused a small non-dose related significant increase in TRAP þve cell number. (C) Examples of TRAP staining in the presence and absence
of RANKL. Scale bar is 100 mm. Data are mean ± SEM, statistical analysis: one way ANOVA, *P < 0.05, **P < 0.01, ***P < 0.001.
L. Xu et al. / Osteoarthritis and Cartilage 24 (2016) 1587e1595 1593small molecule inhibitor attenuates pain behaviour in both the MIA
and surgical MNX models of OA pain26. Control IgG1 treatment did
not alter MIA-induced changes in weight bearing or PWT compared
to PBS treated MIA-injected rats. The inclusion of this additional
control confirms that the effects of muMAb 911 are not due to IgG1
acting as an immunemodulatingdrug, andsupports the specificityof
the inhibitory effects of muMab 911 in MIA-treated rats. These pre-
clinical data are consistent with clinical trials reporting robust anal-
gesic effects of antibodies to NGF in OA sufferers13,14,27 and in dogs28.
The mechanisms by which cutaneous NGFmodulates sensory nerve
terminal excitability, alters gene expression within the dorsal root
ganglia and contributes to the development of chronic pain re-
sponses have beenwell studied8. As described earlier, although there
is evidence for local changes in levels of NGF within the knee joint
contributing to OA pain, the mechanisms by which these changes
result in joint pain are less well characterised. The induction and
release of NGF from human OA chondrocytes following both me-
chanical and inflammatory stimuli has been reported29, which may
be an important source of endogenous NGF in vivo.
Remodeling of the subchondral bone, with initial increases in
subchondral bone resorption and thinning of the subchondral
plate, followed by subchondral sclerosis and osteophyte formation,
is one of the structural features associated with OA30. The signifi-
cant associations between osteoclast numbers and pain behaviour
in OA rats across treatment groups presented herein is consistent
with osteoclasts playing a role in OA pain. Bone is highly innervated
and, unlike cutaneous innervation, the majority of bone sensory
afferents express the cognate receptor for NGF, TrkA31. In addition,
pain-related molecules have been detected in OA subchondral
bone32.The inhibitory effects of muMab 911 on pain behaviour were
associated with a significant decrease in the numbers of TRAP
positive osteoclasts within the subchondral bone, which may sug-
gest that NGF, or factors driven by NGF, contribute to the activation
of osteoclasts in OA. The inhibitory effects of muMab 911 on
numbers of TRAP positive osteoclasts were evident following pre-
ventative treatment, and more importantly following therapeutic
treatment which commenced at a timepoint when osteoclast
number were already significantly elevated. Our data demonstrate
that blockade of NGF can reverse at least one of the bone changes
(increase in osteoclast number) associated with OA21. Osteoclast
activation is associated with reduced extracellular pH and the
release of proteases, and osteoclast products can activate and
sensitize peripheral nerves leading to increased pain signalling33.
Osteoclast inhibitionmight therefore contribute to analgesic effects
of NGF blockade.
The bisphosphonate zoledronate, which targets osteoclasts, has
potential analgesic, as well as structural, benefit in a subgroup of
patients with OAwho display bone marrow lesions on MRI34. Bone
marrow lesions are associated with OA pain35, and are areas of
increased metabolic activity and bone turnover, histologically
characterized by subchondral bone marrow replacement by fibro-
vascular tissue11,23. Although blockade of osteoclast activation and
bone resorption by treatments such as the bisphosphonates inhibit
pathological features of OA and the development of pain behavior
both in OA models24 and in patients36, their analgesic effects are
relatively weak34,36. By contrast, anti-NGF antibody treatments
have robust analgesic effects in clinical trials14 and as demonstrated
herein in this model of OA pain. It is noteworthy that the inhibitory
effects of therapeutic muMab 911 on numbers of TRAP positive
L. Xu et al. / Osteoarthritis and Cartilage 24 (2016) 1587e15951594subchondral osteoclasts were comparable to the inhibitory effects
of therapeutic OPG-Fc treatment on osteoclast number in the same
model6.
Neurotrophins, including NGF, are expressed in subchondral
bone11 and by bone forming cells, and are proposed to have both
autocrine and paracrine roles in bone formation37,38. To further
understand howmuMab 911 inhibits the numbers of TRAP positive
osteoclasts in the MIA model, we undertook an in vitro study to
determine whether NGF can directly alter RANKL mediated differ-
entiation of human monocytes into osteoclasts. Using the same
assay for TRAP staining of multi-nucleated osteoclasts we demon-
strated that a range of concentrations of NGF did not potentiate
RANKLmediated osteoclastogenesis in vitro. Indeed, in the presence
of RANKL, NGF treatment reduced the number of TRAP positive os-
teoclasts. In the absence of RANKL, NGF significantly increased
osteoclast numbers in vitro, but the numbers were far smaller than
when cells were treatedwith RANKL. Our data are consistent with a
previous report that NGF has relatively minor effects on RANKL in-
dependent osteoclastogenesis in vitro39. Given levels of RANKL are
known to be high within the OA knee joint, osteoclastogenesis is
highly likely to occur in the presence of RANKL. The outcomes of our
in vitro assay do not support a direct role of NGF in stimulating
osteoclast function or differentiation in vivo.
muMab 911 treatment did not alter cartilage damage and sy-
novial inflammation, which suggests that the effects of muMab 911
on numbers of osteoclasts within the subchondral bone were not
secondary to modulation of generalised inflammatory processes
within the knee joint. Consistent with other studies, our data
indicate that the effects of NGF on bone turnover are complex and
dependent on the underlying level and mechanisms of bone turn-
over. NGF blockade did not impair fracture repair in animal
models40, but muMab 911 delayed the time to fracture in a
sarcoma-induced bone cancer model18, suggesting that the net
effect of NGF blockademay be neutral, or to increase bone strength.
Collectively, evidence presented herein suggests that at least some
of the subchondral bone changes associated with OA are reversible,
and that inhibiting established OA pain behaviour with muMab 911
has an indirect beneficial effect on subchondral bone remodelling.
Indeed, greater weight bearing in rats treatedwithmuMab 911may
reduce osteoclastic activity and modulate bone turnover, although
the anabolic effects of exercise on bone mineral density may be
predominantly attributable to increased osteoblast, rather than
decreased osteoclast, activity41.
NGF blockade using monoclonal antibodies has been associated
with the rare occurrence of RPOA and further clinical trials for OA
have incorporated appropriate risk mitigation strategies42. Our
study was not designed to investigate rare adverse events. Despite
the lack of significant effects of muMab 911 on joint histopathology
in the current study, other effects might be restricted to discrete
patient subgroups.
In conclusion, we have demonstrated beneficial effects of NGF
blockade using muMab 911 in a rat model of OA pain. In addition to
reducing pain behaviour, preventative and treatment protocols
using muMab 911 reduced numbers of subchondral osteoclasts,
indicating that this bone feature of OA is reversible and that
reducing pain signalling has beneficial effects on subchondral bone
changes associated with OA.
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